These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 33614378)

  • 1. A novel homozygous variant in exon 10 of the
    Dayal D; Gupta S; Kumar R; Srinivasan R; Lorenz-Depiereux B; Strom TM
    Intractable Rare Dis Res; 2021 Feb; 10(1):55-57. PubMed ID: 33614378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperphosphatemic familial tumoral calcinosis caused by a novel variant in the GALNT3 gene.
    Mahjoubi F; Ghadir M; Samanian S; Heydari I; Honardoost M
    J Endocrinol Invest; 2020 Aug; 43(8):1125-1130. PubMed ID: 32125652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case of hyperphosphatemic familial tumoral calcinosis due to maternal uniparental disomy of a
    Nishimura-Kinoshita N; Ohata Y; Sawai H; Izawa M; Takeyari S; Kubota T; Omae Y; Ozono K; Tokunaga K; Hamajima T
    Clin Pediatr Endocrinol; 2023; 32(3):161-167. PubMed ID: 37362161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperphosphatemic Familial Tumoral Calcinosis in Two Siblings with a Novel Mutation in
    Kışla Ekinci RM; Gürbüz F; Balcı S; Bişgin A; Taştan M; Yüksel B; Yılmaz M
    J Clin Res Pediatr Endocrinol; 2019 Feb; 11(1):94-99. PubMed ID: 30015621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term clinical outcome and phenotypic variability in hyperphosphatemic familial tumoral calcinosis and hyperphosphatemic hyperostosis syndrome caused by a novel GALNT3 mutation; case report and review of the literature.
    Rafaelsen S; Johansson S; Ræder H; Bjerknes R
    BMC Genet; 2014 Sep; 15():98. PubMed ID: 25249269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of two novel mutations in the
    Sun L; Zhao L; Du L; Zhang P; Zhang M; Li M; Liu T; Ye L; Tao B; Zhao H; Liu J; Ding X
    Bone Res; 2016; 4():16038. PubMed ID: 27867679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Congenital Hyperphosphatemic Conditions Caused by the Deficient Activity of FGF23.
    Ito N; Fukumoto S
    Calcif Tissue Int; 2021 Jan; 108(1):104-115. PubMed ID: 31965220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoimmune hyperphosphatemic tumoral calcinosis in a patient with FGF23 autoantibodies.
    Roberts MS; Burbelo PD; Egli-Spichtig D; Perwad F; Romero CJ; Ichikawa S; Farrow E; Econs MJ; Guthrie LC; Collins MT; Gafni RI
    J Clin Invest; 2018 Dec; 128(12):5368-5373. PubMed ID: 30226830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three Siblings With a Rare Familial Hyperphosphatemia Syndrome: A Case Series.
    Sowaity ZA; Saleem JY; Sabooh TN; Dukmak ON; Abu Al-Saoud SY
    Cureus; 2024 Mar; 16(3):e55575. PubMed ID: 38576700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Familial tumoral calcinosis caused by a novel FGF23 mutation: response to induction of tubular renal acidosis with acetazolamide and the non-calcium phosphate binder sevelamer.
    Lammoglia JJ; Mericq V
    Horm Res; 2009; 71(3):178-84. PubMed ID: 19188744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperphosphatemic familial tumoral calcinosis caused by a mutation in GALNT3 in a European kindred.
    Specktor P; Cooper JG; Indelman M; Sprecher E
    J Hum Genet; 2006; 51(5):487-490. PubMed ID: 16528452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case of familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome due to a compound heterozygous mutation in GALNT3 demonstrating new phenotypic features.
    Dumitrescu CE; Kelly MH; Khosravi A; Hart TC; Brahim J; White KE; Farrow EG; Nathan MH; Murphey MD; Collins MT
    Osteoporos Int; 2009 Jul; 20(7):1273-8. PubMed ID: 18982401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutations.
    Ichikawa S; Baujat G; Seyahi A; Garoufali AG; Imel EA; Padgett LR; Austin AM; Sorenson AH; Pejin Z; Topouchian V; Quartier P; Cormier-Daire V; Dechaux M; Malandrinou FCh; Singhellakis PN; Le Merrer M; Econs MJ
    Am J Med Genet A; 2010 Apr; 152A(4):896-903. PubMed ID: 20358599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperphosphatemic familial tumoral calcinosis secondary to fibroblast growth factor 23 (FGF23) mutation: a report of two affected families and review of the literature.
    Chakhtoura M; Ramnitz MS; Khoury N; Nemer G; Shabb N; Abchee A; Berberi A; Hourani M; Collins M; Ichikawa S; El Hajj Fuleihan G
    Osteoporos Int; 2018 Sep; 29(9):1987-2009. PubMed ID: 29923062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Miscellaneous non-inflammatory musculoskeletal conditions. Hyperphosphatemic familial tumoral calcinosis (FGF23, GALNT3 and αKlotho).
    Farrow EG; Imel EA; White KE
    Best Pract Res Clin Rheumatol; 2011 Oct; 25(5):735-47. PubMed ID: 22142751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defective O-glycosylation of novel FGF23 mutations in a Chinese family with hyperphosphatemic familial tumoral calcinosis.
    Liu C; Pang Q; Jiang Y; Xia Y; Fang L; Wang O; Li M; Xing X; Gong Y; Xia W
    Bone; 2020 Aug; 137():115401. PubMed ID: 32360901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperphosphatemic Tumoral Calcinosis: Pathogenesis, Clinical Presentation, and Challenges in Management.
    Boyce AM; Lee AE; Roszko KL; Gafni RI
    Front Endocrinol (Lausanne); 2020; 11():293. PubMed ID: 32457699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GALNT3, a gene associated with hyperphosphatemic familial tumoral calcinosis, is transcriptionally regulated by extracellular phosphate and modulates matrix metalloproteinase activity.
    Chefetz I; Kohno K; Izumi H; Uitto J; Richard G; Sprecher E
    Biochim Biophys Acta; 2009 Jan; 1792(1):61-7. PubMed ID: 18976705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel mutations in GALNT3 causing hyperphosphatemic familial tumoral calcinosis.
    Yancovitch A; Hershkovitz D; Indelman M; Galloway P; Whiteford M; Sprecher E; Kılıç E
    J Bone Miner Metab; 2011 Sep; 29(5):621-5. PubMed ID: 21347749
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.